Relationship Between Anemia, B-Type Natriuretic Peptide Level and Physical Functioning in Heart Failure

Yıl 2015, Cilt: 24 Sayı: 2, 171 - 181, 05.03.2015

Derya Atik , Hilal Kuşçu Karatepe

https://doi.org/10.17827/aktd.37933

Öz

Heart failure is a complex clinical condition caused by structural or functional changes affecting the dilatation and/or ejection ability of the ventricle. Anemia and B-type natriuretic peptide (BNP) levels are commonly observed conditions in heart failure, affecting quality of life, physical functioning, mortality, and morbidity. In cases with heart failure, it is important that nurses and other healthcare personnel closely monitor anemia and BNP values that are closely associated with functional capacity. This article focuses on the association between heart failure and anemia and BNP level, and its effect on physical function, considering that the results will provide guidance for nurses and healthcare professionals in patient monitoring, treatment and care planning.

Anahtar Kelimeler

Heart Failure, Anemia, Type B natriüretik peptide, Nursing

Kalp Yetersizliğinde Anemi ve B Tipi Natriüretik Peptid Düzeyinin Fiziksel Fonksiyon ile İlişkisi

Öz

Kalp yetersizliği, ventrikülün doluş ve/veya ejeksiyon yetisini etkileyen yapısal veya fonksiyonel değişikliklerin neden olduğu kompleks bir klinik durumdur. Anemi ve B tipi natriüretik peptid (BNP) düzeylerindeki değişimler yaşam kalitesi, fiziksel fonksiyon, mortalite ve morbiditeyi etkileyen durumlardır. Kalp yetersizliği olgularında hemşirelerin ve diğer sağlık çalışanlarının; fonksiyonel kapasiteyle yakından ilişkili olan anemi ve BNP değerlerini yakından takip etmesi önemlidir.Bu makalede; hemşire ve sağlık çalışanlarının hasta takibi, tedavisi ve bakım planlamalarına rehber olacağı düşüncesiyle, anemi ve BNP düzeyinin kalp yetersizliği ile birlikteliği, fiziksel fonksiyon düzeyine etkisi üzerinde durulacaktır.

Anahtar Kelimeler

Kalp Yetersizliği, Anemi, B Tipi Natriüretik Peptid, Hemşirelik

Kaynakça

• Abete P, Testa G, Della-Morte D, Gargiulo G, Galizia G, de Santis D et al. Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev. 2013;18:529-51.
• Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK et al. Heart failure prevalence and predictors in Turkey (HAPPY) çalışması. Turk Kardiyol Dern Ars. 2012;40:298-308.
• Sata Y, Krum H. The future of pharmacological therapy for heart failure. Circ J. 2010;74:809-17.
• Anker SD, John M, Pedersen PU, Raguso C, Cicoira M, Dardai E et al. ESPEN Guidelines on enteral nutrition: Cardiology and pulmonology. Clin Nutr. 2006;25:311-8.
• Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1451-9.
• Carels RA, Musher-Eizenman D, Cacciapaglia H, Perez-Benitez CI, Christie S, O'Brien W. Psychosocial functioning and physical symptoms in heart failure patients: a within-individual approach. J Psychosom Res. 2004;56:95-101.
• Dixon T, Lim LL, Powell H, Fisher JD. Psychosocial experiences of cardiac patients in early recovery: a community-based study. J Adv Nurs. 2000;31:1368-75.
• Murberg TA, Bru E, Aarsland T, Svebak S. Social support, social disability and their role as predictors of depression among patients with congestive heart failure. Scand J Soc Med. 1998;26:87-95.
• Maisel A. B type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clinics. 2001;19:557-71.
• Wieczorek SJ, Bailly KR, Thomas P, Wu AHB, Hager D, Ferrier A et al. Clinical evaluation of the Triage B type natriuretic peptide assay for point of core testing of patients with congestive heart failure. Clin Chem. 2000;46:A77.
• Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818-27.
• Adams KF, Pina IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA et al. Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J. 2009;158:965-71.
• Lifton RP. Moleculer genetics of human blood pressure variation. Science. 1996;272:676-80.
• Szachniewicz J, Petruk-Kowalczyk J, Majda J, Kaczmarek A, Reczuch K, Kalra PR et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol. 2003;90:303-8.
• Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15:14-8.
• Ghali JK. Anemia and poor prognosis in advanced heart failure. J Am Coll Cardiol. 2002;40:2204.
• Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:1-194.
• Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1440-6.
• Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107:223-5.
• Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107:226-9.
• Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103-12.
• Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436- 48.
• Lawler PR, Filion KB, Eisenberg MJ. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents. J Card Fail. 2010;16:649-58.
• Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-44.
• Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-9.
• Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-80.
• Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625-8.
• Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival in partients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J. 2004;25:1021-8.
• Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J. 1993;70:357-62.
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-8.
• Gürgün C. Uzman yanıtları. Türk Kardiyol Dern Arş. 2008;36:433-4.
• Von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1973-80.
• Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40.
• de Lemos JA, Mcguire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
• Eichhorn EJ. Prognosis determination in heart failure. Am J Med. 2001;110:14-36.
• Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
• Stein BC, Levi RI. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J. 1998;135:914-23.
• Krüger S, Graf J, Kunz D, Stickel T, Hanrath P, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:718-22.
• Smart NA, Steele M. Systematic review of the effect of aerobic and resistance exercise training on systemic brain natriuretic peptide (BNP) and N-terminal BNP expression in heart failure patients. Int J Cardiol. 2010;140:260-5.
• Nilsson BB, Westheim A, Risberg MA, Arnesen H, Seljeflot I. No effect of group-based aerobic interval training on N-terminal pro- B-type natriuretic peptide levels in patients with chronic heart failure. Scand Cardiovasc J. 2010;44:223-9.
• Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P et al. BNP-guided vs symptom- guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301:383-92.
• Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP)concentrations. Lancet. 2000;355:1126-30.
• Savarese G,Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013;8:e58287.
• Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587-93.
• Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
• Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 2001;38:436-42.
• Correspondence Address / Yazışma Adresi